Pleurectomy/decortication
Progress in the understanding of the immune microenvironment and immunotherapy in malignant pleural mesothelioma
Current Drug Targets 2020 July 18 [Link] Lei Cheng, Li Na, Xiao-Ling Xu, Wei-Min Mao Abstract Malignant pleural mesothelioma (MPM) is a remarkably aggressive thoracic malignancy with a limited survival of only 5-12 months. However, MPM still remains unresponsive to conventional standards of treatment, including pleurectomy and decortication, extrapleural pneumonectomy for resectable disease with or…
Read MoreSurgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
Translational Lung Cancer Research 2020 February [Link] Woodard GA, Jablons DM Abstract Extrapleural pneumonectomy (EPP) and pleurectomy decortication (PD) are radical operations for malignant pleural mesothelioma (MPM) that remain controversial among thoracic surgeons. There is a lack of randomized evidence to support a survival benefit when major surgical resection is included in multi-modality treatment regimens.…
Read MoreRoutine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.
The Journal of Thoracic and Cardiovascular Surgery 2020 January 30 [Link] De León LE, Bravo-Iñiguez CE, Fox S, Tarascio J, Freyaldenhoven S, Lapidot M, Jaklitsch MT, Bueno R Abstract OBJECTIVE: The purpose of this study was to determine the incidence of venous thromboembolism and utility of a routine surveillance program in patients undergoing surgery for…
Read MoreDisease-Related Outcomes and Toxicities of Intensity-Modulated Radiation Therapy Following Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review.
Practical Radiation Oncology 2020 February 20 [Link] Patel R, Ludmir EB, Miccio JA, Menon H, Barsky AR, Mesko SM, Kodali M, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Verma V Abstract PURPOSE: To explore the use of intensity-modulated radiotherapy (IMRT) after lung-sparing surgery in malignant pleural mesothelioma (MPM). Because severe toxicities have been documented following…
Read MoreImpressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Lung Cancer 2020 February 14 [Link] Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L Abstract OBJECTIVES: Treatment options for malignant pleural mesothelioma (MPM) are limited but some studies on immune checkpoint inhibitors (ICIs) in MPM have reported…
Read MoreClinical outcomes with recurrence after pleurectomy/decortication for malignant pleural mesothelioma.
Annals of Thoracic Surgery 2020 January 16 [Link] Nakamura A1, Takuwa T2, Hashimoto M2, Kuroda A2, Nakamichi T2, Matsumoto S2, Kondo N2, Kijima T3, Yamakado K4, Hasegawa S2. Abstract BACKGROUND: Most patients with malignant pleural mesothelioma experience recurrence following treatment. However, no clinical studies have evaluated post-recurrence survival after pleurectomy/decortication for malignant pleural mesothelioma. This…
Read MorePosterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma.
The Annals of Thoracic Surgery 2019 October 18 [Link] Friedberg JS, Simone CB 2nd, Culligan MJ, Putt ME, Barsky AR, Katz S, Cengel KA Abstract BACKGROUND: Posterior intercostal lymph nodes, previously undescribed for cancer staging, are part of the lymphatic drainage of the pleural space. The purpose of this study was to assess the impact…
Read MoreTypes of surgery post-neoadjuvant chemotherapy for pleural mesothelioma.
Expert Review of Respiratory Medicine 2019 October 9 [Link] Kuribayashi K, Doi H, Kijima T Abstract Introduction: The surgical arm of the Mesothelioma and Radical Surgery (MARS) trial involved a multimodal approach, with combined therapy consisting of chemotherapy, complete gross resection, and radiation therapy. However, the MARS trial did not compare surgery with chemotherapy, and…
Read MoreVolumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.
Clinical Lung Cancer 2019 September 5 [Link] Franceschini D, De Rose F, Cozzi S, Renna I, Franzese C, Di Brina L, Navarria P, D’Agostino GR, Mancosu P, Tomatis S, Scorsetti M Abstract INTRODUCTION: We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM)…
Read MorePleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.
Journal of Thoracic Disease 2019 May [Link] Klotz LV, Lindner M, Eichhorn ME, Grützner U, Koch I, Winter H, Kauke T, Duell T, Hatz RA Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with few long-term survivors. Despite the dismal prognosis, hyperthermic intrathoracic chemoperfusion (HITHOC) was shown to improve survival in a selective…
Read More